UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Therapy for isocitrate dehydrogenase 2 (IDH2)(R172)-mutant acute myeloid leukaemia

Linch, DC; Hills, RK; Burnett, AK; Russell, N; Gale, RE; (2021) Therapy for isocitrate dehydrogenase 2 (IDH2)(R172)-mutant acute myeloid leukaemia. British Journal of Haematology 10.1111/bjh.17981. (In press). Green open access

[thumbnail of Gale_Therapy for isocitrate dehydrogenase 2 (IDH2)^{R172}-mutant acute myeloid leukaemia_AOP.pdf]
Preview
Text
Gale_Therapy for isocitrate dehydrogenase 2 (IDH2)^{R172}-mutant acute myeloid leukaemia_AOP.pdf - Published Version

Download (361kB) | Preview

Abstract

Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2)R172-mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2WT and IDH2R140-mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2R172 AML. We found an improved outcome for IDH2R172-mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.

Type: Article
Title: Therapy for isocitrate dehydrogenase 2 (IDH2)(R172)-mutant acute myeloid leukaemia
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/bjh.17981
Publisher version: https://doi.org/10.1111/bjh.17981
Language: English
Additional information: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: acute myeloid leukaemia; isocitrate dehydrogenase 2 (IDH2)R172 mutations; prognostic impact; optimal therapy; allogeneic transplantation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10140354
Downloads since deposit
6,460Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item